WO2012013763A2 - Utilisation d'un mélange de grains de café torréfiés et de grains de café verts pour réguler la pigmentation de la peau - Google Patents

Utilisation d'un mélange de grains de café torréfiés et de grains de café verts pour réguler la pigmentation de la peau Download PDF

Info

Publication number
WO2012013763A2
WO2012013763A2 PCT/EP2011/063060 EP2011063060W WO2012013763A2 WO 2012013763 A2 WO2012013763 A2 WO 2012013763A2 EP 2011063060 W EP2011063060 W EP 2011063060W WO 2012013763 A2 WO2012013763 A2 WO 2012013763A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
coffee
accordance
roasted
coffee beans
Prior art date
Application number
PCT/EP2011/063060
Other languages
English (en)
Other versions
WO2012013763A3 (fr
Inventor
Karin Kraehenbuehl
Olivier Mauroux
Angus Moodycliffe
Fabiola Dionisi
Marjorie Guitard
Original Assignee
Nestec S.A.
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec S.A., L'oreal filed Critical Nestec S.A.
Priority to MX2013001076A priority Critical patent/MX350476B/es
Priority to JP2013521152A priority patent/JP2013537528A/ja
Priority to BR112013002326-0A priority patent/BR112013002326B1/pt
Priority to EP11739045.0A priority patent/EP2598105A2/fr
Priority to RU2013108970/15A priority patent/RU2013108970A/ru
Priority to CN201180037632.XA priority patent/CN103068360B/zh
Publication of WO2012013763A2 publication Critical patent/WO2012013763A2/fr
Publication of WO2012013763A3 publication Critical patent/WO2012013763A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention relates generally to the field of food supplements and/or food products for cosmetic purpose. More specifically, the present invention aims to provide an ingredient containing a mixture of roasted and green coffee beans for preventing and/or treating hyper- pigmentation of skin, skin color imperfections such as age-spots and other skin disorders characterized by abnormal pigments. The present invention also aims at improving skin tone as well as providing a skin lightening or whitening agent. Background of the invention
  • Skin color is primarily determined by the amount and type of melanin, a brown pigment present in the skin. Lower amounts of melanin result in lighter skin color while higher amounts result in darker skin color. Also, hyper-pigmentation in the skin is caused by the over expression or accumulation of melanin in the skin. As a result, the pathway involved in melanin production has been the target for many inhibitors so as to reduce the levels produced.
  • One of the principal enzymes involved in the melanin pathway is tyrosinase.
  • melanin is a process under hormonal control, including the melanocyte stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) peptides that are produced from the precursor proopiomelanocortin. It is stimulated by the DNA damages that are caused by UVB-radiations as well.
  • MSH melanocyte stimulating hormone
  • ACTH adrenocorticotropic hormone
  • tyrosinase inhibitors such as hydroquinone, vitamin C, cystein, kojic acid, arbutin and glutathione among others have been proposed in topical compositions.
  • tyrosinase inhibitors such as hydroquinone, vitamin C, cystein, kojic acid, arbutin and glutathione among others have been proposed in topical compositions.
  • a variety of dermatological compositions have been suggested for improving the appearance of pigment disorders such as that observed in melasma, freckles, vitiligo, piebaldism, phenylketonuria, and the like, and/or for cosmetic purposes.
  • Topical retinoid and topical corticosteroids have been suggested as hypo-pigmenting agents, as have laser treatment and chemical peels, but these fall short of desirable responses.
  • Other compositions suggested the use on the skin of natural materials, which have in some cases been used for centuries in Asia or Europe to bleach skin and skin areas, or enhance the appearance of fair skin. These include the use of lemon, orange, cucumber, ginkgo, carob, rose fruit, geranium herb, cinnamon, sweet marjoram, rosemary, etc...
  • various compounds which, when applied topically to the skin, are capable of reducing tyrosinase activity and consequently limiting melanin production, have thus been proposed.
  • the treatments currently available are not entirely satisfactory, in particular in terms of the side effects which are frequently associated therewith, such as irritant side effects with certain topical agents.
  • the present inventors could achieve this object by providing a food or food supplement composition that comprises at least an ingredient containing a mixture of roasted and green coffee beans.
  • the invention relates to the cosmetic use of an effective amount of at least an ingredient containing roasted and green coffee portions as an active agent for treating and/or preventing skin pigmentation disorders.
  • skin disorder are in particular those due to age or to environmental factors (e.g. UV), such as age-spots. It may also be skin disorders that are observed in melasma, freckles, vitiligo, piebaldism, phenylketonuria, and the like.
  • the present inventors have discovered that mixture of unroasted and roasted coffee beans effectively suppress the formation of melanin, melanogenesis, despite the fact that the extracts show little to no inhibition of tyrosinase activity. This result is surprising and unexpected considering the pivotal role of tyrosinase in melanogenesis and the focus of development efforts in the art to inhibit this enzyme.
  • skin is intended to mean the skin of the face or of the body.
  • the term "effective amount”, is intended to mean an amount sufficient to obtain the expected effect.
  • the term "prevent” is intended to mean the fact of reducing the risk of occurrence of the manifestation of the disorder under consideration.
  • the present invention is also directed towards the cosmetic use of the abovementioned ingredient, as an active agent for treating and/or preventing the skin pigment imperfections.
  • the complexion becomes brighter and more homogeneous, without areas of dyschromia, or of dryness.
  • the present invention is also directed towards the cosmetic use of an effective amount of at least an ingredient containing unroasted and roasted coffee portions according to the invention, as an active agent for whitening or lightening skin tone.
  • the present inventors have also discovered that the ingredient according to the invention further improves hydration and/ or skin barrier function.
  • a use in accordance with the present invention may also comprises the use of at least an ingredient containing green and roasted coffee portions, in combination with an effective amount of at least one active agent for further improving skin hydration or skin ageing, in particular as described hereinafter.
  • the subject of the invention is a method, in particular a cosmetic method, for treating and/or preventing skin tone imperfections and the disorders associated with hyper-pigmentation, in particular aesthetic disorders, in an individual, comprising at least one step of administering, to said individual, at least an ingredient containing unroasted and roasted coffee portions according to the invention.
  • compositions according to the present invention are orally administrable. This has the advantage of acting globally on the entire skin, in its deep layers (dermis, hypodermis), by means of a rapid and relatively non-restrictive mode of administration. Specifically, the metabolites and other active nutriments are in particular distributed within the dermal matrix by means of the bloodstream. Oral administration also has the advantage of a rapid and relatively non-restrictive mode of administration.
  • the present invention provides the use of a coffee product which depends upon the blending of coffee beans, a portion of which are roasted and portion of which are unroasted or green.
  • coffee beans must be understood to mean the bean obtained by the moist route (fermentation, washing) or by the dry route (drying followed by mechanical husking) starting from the coffee "cherry”, after husking as described above.
  • Extract must be understood to mean all of the compounds obtained starting from an alcoholic or aqueous-alcoholic extraction of a crude product, in this instance decaffeinated coffee beans, roasted or unroasted.
  • the species of coffee trees selected for the preparation of the extracts of coffee beans used in the compositions are advantageously selected from the Coffea species.
  • Coffee trees are small trees with smooth-margined, perennial, coriaceous, glossy leaves (10- 15 x 4-6 cm). The white, fragrant flowers are grouped in whorls at the axil of the leaves. The fruit is a green drupe, which becomes red at maturity and usually contains two planar-convex berries which are made contiguous through their planar face. Although only two species supply the essential needs of the coffee market (C. arabica and C. canephora), many species of coffee trees exist in the wild state in the tropical forests of East Africa. The coffee "bean” is obtained by the moist route (fermentation, washing) or the dry route (drying, followed by mechanical decortication) starting from the coffee"cherry", i.e. from the drupes.
  • the green coffee portion may be a blend of green Arabica and green Robusta beans.
  • the green coffee portion is substantially or wholly derived from Robusta coffee beans.
  • at least 65%, more preferably 75%, even more preferably 85%, most preferably 95%, e.g. 100% by weight of the green coffee beans are Robusta.
  • the roasted coffee portion may be a blend of Arabica and Robusta, although it is particularly preferred that the roasted portion is substantially or wholly derived from Arabica beans. This is because Arabica provides a richer taste and aroma profile, which is associated with coffee of higher quality.
  • the roasted coffee may have different roasting levels form light to dark, preferably CTN from 60 to 100.
  • the green coffee portion and/or the roasted coffee portion may be at least partially decaffeinated. This is to provide products the caffeine level of which can be modulated from caffeine-free to regular caffeine level. However, it is particularly preferred that the green coffee portion is from decaffeinated coffee.
  • a coffee bean extract can be obtained by an aqueous- alcoholic or alcoholic extraction of coffee beans, and preferably by an extraction with the aid of methanol, ethanol or propanol. Preferably, it does not contain the fractions of coffee beans extractable by non- polar solvents. Methods for the preparation of decaffeinated coffee extracts are well known in the art.
  • the coffee product is derived from a mixture of green and roasted coffee beans in which the weight ratio of the green portion and roasted portion in the coffee product is from 1 :99 to 90:10, preferably from 30:70 to 50:50, more preferably from 35:65 to 45:55, most preferably from 37:63 to 42:58.
  • Such coffee product is described in EP1871173 which is included by reference.
  • the coffee product preferably comprises:
  • a first portion consisting of unroasted ground and/or unground coffee, in an amount of from 1 to 90 % by wei g ht based o n the total wei g ht of the coffee prod uct
  • a second portion consisting of ground coffee which has been roasted to a higher degree of roast than said first portion, in an amount of from 99 to 10% by weight based on the total weight of the coffee product
  • chlorogenic acids are present in an amount of at least 2g per 100g of the coffee product, more preferably at least 4g, even more preferably at least 6g, most preferably at least 8g, e.g. at least 9g.
  • compositions according to the invention may be in any of the galenical forms normally available for the method of administration selected.
  • the carrier may be of diverse nature depending on the type of composition under consideration.
  • the composition may be any food or pharmaceutical product, or a cosmetic product for oral application.
  • food or pharmaceutical carriers nutritional complete formula, dairy product such as milk, yogurt, cheese, fermented milks, milk-based fermented products, icecreams, cereal-based products or fermented cereal-based products, milk-based powders, infant and baby formulas, chilled or shelf stable beverages, food products of confectionary, chocolate or cereal type, animal feed, in particular for domestic animals.
  • the chicory or extract thereof may be incorporated into any other form of food supplement or enriched food , for example food bars or compacted or non-compacted powders.
  • the powders may be diluted in water, soda, milk products or soya bean derivatives, or be incorporated into food bars.
  • the food product may also further comprise a protein source, a carbohydrate source, a lipid source, a mineral source and/or a vitamin source.
  • a protein source a carbohydrate source
  • a lipid source a mineral source and/or a vitamin source.
  • proteins, carbohydrates, lipids, minerals and/or vitamins may have several advantages. These compounds generally contribute to the taste and mouthfeel of the final product. They also provide the body with nutrients that it may need urgently when it is affected by skin disorders. They also allow formulating the product of the present invention as a complete nutritional formula, so that no additional nutrition is needed.
  • the individual ingredients may comprise any kind of edible compound.
  • Typical ingredients for food compositions, in particular drinks are well known in the art, e.g. milk, cream, coffee whiteners, and coffee creamers.
  • ingredients could also be a salad dressing or parts thereof, for example.
  • Such compounds are used by consumers to modify e.g. the aroma, appearance and texture of a composition.
  • the ingredients may be in liquid or dry form, e.g. as powders, that are dissolved and/or suspended in a drink.
  • the invention also provides a coffee beverage product, such as (a) a roast and ground coffee product, (b) a soluble coffee product, (c) a single portion coffee pad, tablet or capsule (d) a ready to drink coffee product or (e) any other suitable coffee product, comprising the coffee product as defined herein as an ingredient.
  • Soluble coffee or instant coffee as it is otherwise known, is very well known and has been produced commercially for many decades. It is produced from roast and ground coffee in a vari ety of ways , al l of wh i ch a re we l l kn own to th e pe rso n s ki l l ed i n th e a rt .
  • the present invention is particularly suitable for use as a soluble coffee product or any product, which is based on or derived from a soluble coffee product.
  • the coffee product may also be used in so-called ready-to-drink beverages.
  • ready-to-drink beverages for which the product of the present invention are suited include two-in-one beverages which comprise a coffee component together with a natural or artificial sweetener component, the components optionally being pre-diluted with a liquid such as water or milk.
  • the coffee component can comprise the coffee product of the present invention.
  • Three-in-one beverages which comprise coffee, a sweetener and a whitener such as milk, a liquid creamer or a solid (e.g. powdered) creamer, may comprise the coffee product of the present invention.
  • any beverage which comprises soluble coffee as an ingredient, may comprise the coffee product of the present invention.
  • the composition may further comprise further ingredient suitable for inclusion in a food composition.
  • Usual ingredients may e.g. be sugars, artificial sweeteners, emulsifiers, stabilizers, thickeners, flowing agents, colors, flavors, aromas, and the like.
  • Suitable artificial sweeteners include saccharin, cyclamates, acetosulfame, L-aspartyl based sweeteners such as aspartame, and mixtures of these.
  • Suitable emulsifiers include monoglycerides, diglycerides, lecithin, diacetyl tartaric acid esters of mono-diglycerides, emulsifying starches, and mixtures thereof.
  • Suitable stabilisers include dipotassium phosphate and sodium citrate.
  • a suitable flowing agent is sodium silica aluminate.
  • the composition comprises milk protein and/or vegetable protein.
  • the composition comprises milk fat and/or vegetable fat.
  • the present invention can be used as an ingredient for standard brew, espresso, coffee-based beverage preparations to be used as bulk or in single beverage portion for in- home preparation.
  • the product is a nutritional supplement for oral administration it may be present in capsules, gelatin capsules, soft capsules, tablets, sugar-coated tablets, pills, pastes or pastilles, gums, or drinkable solutions or emulsions, a syrup or a gel.
  • a supplement might also include a sweetener, a stabilizer, an antioxidant, an additive, a flavoring agent and/or a colorant.
  • the formulation thereof is carried out by means of the usual methods for producing sugar-coated tablets, gel capsules, gels, hydrogels for controlled release, emulsions, tablets or capsules.
  • the adjuvant for oral compositions, in particular for dietary supplements are known to the specialist.
  • lubricants such as magnesi um stearate, products for instantaneous solubilisation, gelling agents, thickeners, moisturizers, fatty and/or aqueous compounds, preservatives, texturizing, flavoring and/or coating agents, anti-oxidants and coloring materials usually used in foods.
  • composition according to the present invention may contain, in addition, lipids, polyphenols, taurine, probiotic microorganisms, vitamins and/or oligo-elements. If probiotics are used, they may be included in a live form, semi-active or in a desactivated form, e. g., as a lyophilized powder. Also culture supernatants of the micro-organisms may be included in the composition.
  • Lactic acid bacteria in particular Lactobacilli and/or Bifidobacteria and are more preferably selected among the group consisting of Lactobacillus johnsonii, Lactobacilus reuteri , Lactobacillus rhamnosus, Lactobacillus paracasei , Lactobaci ll us casei , Bifidobacteri um bifidu m , Bifidobacteri u m breve, Bifidobacterium animais, Bifidobacterium infantis, Bifidobacterium dolescentis and Bifidobacterium pseudocatenulatum.
  • the strains used are Lactobacillus johnsonii (La1) deposited on June 30, 1992, under Budapest Treaty with the Institute Pasteur and receiving the deposit no. CNCM 1-1225 or Lactobacillus paracasei (ST1 1) deposited on January 12, 1999, with the Institute Pasteur according to the Budapest Treaty and receiving the deposit no. CNCM I- 2116.
  • the following compounds may for example be used alone or in combination: zinc and its salts including zinc sulfate and zinc glucanate, the vitamins B5, B6, B8, C, E or PP, p-carotene and the carotenoids, extracts of garl ic in particular in the form of allyl sulfide or oi l garlic, selenium , curcumi n, the curcuminoids, niacin, lithospermic acid and adenosine. It is understood that the specialist will select such active compounds and, where possible, combine them in such a manner as to improve the effects expected of the composition which is the object of the invention by preventing the desired activity of interest from being inhibited or attenuated.
  • zinc and its salts including zinc sulfate and zinc glucanate
  • the vitamins B5, B6, B8, C, E or PP p-carotene and the carotenoids
  • extracts of garl ic in particular in the form of allyl s
  • the products of the invention may be efficiently used for treating or preventing skin pigmentation disorders or cosmetically lightening skin tone e.g. by decreasing the production of melanin.
  • melanin Indeed blends of roasted and unroasted (green) coffee beans were shown to decrease in vitro the synthesis of melanin (Example 1 , Figure 1 ) .
  • the production of tyrosinase was also decreased but to a lim ited extent ( Figure 2), suggesting that the decrease in melanin was not due to tyrosinase inhibition but rather to mechanisms acting upstream or downstream of this enzyme.
  • the ingredients according to the present invention have further a positive effect on strengthening skin barrier and maintaining skin hydration.
  • the invention relates to the cosmetic use of an effective amount of at least one ingredient containing roasted and unroasted coffee beans as an active agent for treating and/or preventing skin pigmentation disorders, in particular those due to age or environmental factors such as UV.
  • the present invention is also directed towards the cosmetic use of an effective amount of at least one ingredient containing roasted and unroasted coffee beans as an active agent for whitening or lightening skin tone, which is particularly desirable for asian population.
  • a use in accordance with the present invention may also comprises the use of at least one ingredient containing roasted and unroasted coffee beans, in combination with an effective amount of at least one active agent for improving skin hydration or skin ageing, in particular as described hereinafter.
  • the subject of the invention is a method, in particular a cosmetic method, for treating and/or preventing skin tone imperfections and/or disorders associated with hyper-pigmentation, in particular aesthetic disorders, in an individual , comprising at least one step of administering, to said individual, at least one ingredient containing roasted and unroasted coffee beans according to the invention.
  • the cosmetic treatment method of the invention may be carried out in particular by orally administering at least an effective amount of at least one ingredient containing roasted and unroasted coffee beans in accordance with the invention.
  • Oral administration comprises ingesting, in one or more intakes, an oral composition as defined above. It may comprise a single application. According to another embodiment, the application is repeated, for example, 2 to 3 times a day, for one day or more, and generally for a sustained period of at least 4, or even 1 to 15, weeks.
  • a topical or oral treatment with a composition containing roasted and unroasted coffee beans in accordance with the invention, combined with an oral or topical composition optionally containing another active ingredient, in particular a probiotic microorganism, or other probiotics in dead, live or semi-active form or an hydrating or anti-ageing agent could be imagined as a kit.
  • the ingredients are mixed, before they are formulated, in the order and under conditions readily determined by those skilled in the art.
  • the ingredients are mixed, before they are formulated, in the order and under conditions readily determined by those skilled in the art.
  • the proportion of coffee bean extract in the composition will of course be determined as a function of the desired effect and on the mode of administration of the composition.
  • the daily doses of coffee bean extract administered by the oral route may preferably be comprised between 0.01 and 5000 mg/day depending on the caffeine content.
  • the coffee bean blend is present in the composition according to the invention in a quantity permitting its administration at a dose comprised between 0.5 and 1000 mg/day.
  • the present inventors have found that the effectiveness of the coffee bean blend according to the present invention is generally dose dependant and follows a dose response curve. If generally mild skin disorders or damages are to be prevented and the product will be used frequently, very small amounts will be sufficient to achieve the desired effect. If a severe skin pigment disorder is to be treated, larger amounts will be more appropriate, although also small amounts will produce an effect.
  • the composition intended for oral administration contains an extract of coffee beans in a quantity ranging from 10% to 100% by weight of the composition and preferably from 20 % to 80% by weight of the composition depending on the product form (soluble coffee, RTD, coffee mixes, food product or food supplement).
  • extract of coffee beans in a quantity ranging from 10% to 100% by weight of the composition and preferably from 20 % to 80% by weight of the composition depending on the product form (soluble coffee, RTD, coffee mixes, food product or food supplement).
  • Figure 1 Assessment of melanin production by murine melanocytes pre-treated with coffee blends.
  • Figure 2 Assessment of tyrosinase production by murine melanocytes pre-treated with coffee blends.
  • Figure 3 Assessment of filaggrin synthesis by human primary epidermal keratinocytes pre- treated with coffee blends.
  • Figure 4 Assessment of hyaluronic acid secretion by human primary epidermal keratinocytes pre-treated with coffee blends.
  • B16 cells were cultured in DMEM 1 g/L glucose without phenol red supplemented with 10 % foetal calf serum, in a humidified chamber at 37 °C and containing 5% C02. 2. The production of melanin by B16 murine melanocyte cell line.
  • INGREDIENTS We have tested coffee blends including PROTECT® extract (Nestle Green blend) as well as other blends e.g Stevol (provided by Naturex) and Oryza's Extract-P. The tested concentrations for each coffee extract is indicated in Table 1. Highest Highest
  • Results Results are expressed in percentage relative to the control.
  • Test reference Karlin
  • Figure 1 shows the melanin production by B16 melanocytes treated for 72 hours with the selected ingredients.
  • coffee extracts had some potential for skin de-pigmentation as they were able to decrease the production of melanin and tyrosinase in vitro compared to control conditions ( Figures 1 and 2).
  • Some extracts including Protect and roasted coffee brews, decreased the melanin content without affecting tyrosinase production, suggesting mechanisms acting upstream or downstream tyrosinase.
  • Exemple 2 Effect on skin barrier function and hydration
  • the potential beneficial effect of the Extracts of Example 1 towards skin barrier function and skin hydration was evaluated by using 2D culture of human primary epidermal keratinocytes and we performed 2 tests: 1- assessment of the synthesis of filaggrin and 2- assessment of the secretion of hyaluronic acid by human primary epidermal keratinocytes.
  • the cell culture conditions The cell culture conditions.
  • Human epidermal keratinocytes were cultured in control keratinocytes-SFM medium, in a humidified chamber at 37 °C and containing 5% C02. The synthesis of filaggrin by human epidermal keratinocytes.
  • Caffeine is then removed by supercritical chromatography (C02 is used as carrier gas). 25.5 grams of active extract called “decaffeinated lyophilized extract” are thus obtained.
  • One stick can be taken per day.

Abstract

La présente invention a trait de manière générale au domaine des compléments alimentaires et/ou des produits alimentaires à usage cosmétique. L'invention vise plus particulièrement à procurer un ingrédient contenant un mélange de grains de café torréfiés et de grains de café non torréfiés pour prévenir et/ou traiter une hyperpigmentation de la peau, des défauts de carnation tels que des taches de vieillesse et d'autres affections cutanées caractérisées par des pigments anormaux. La présente invention vise également à améliorer le teint et à procurer un agent d'éclaircissement ou de blanchiment de la peau.
PCT/EP2011/063060 2010-07-30 2011-07-29 Utilisation d'un mélange de grains de café torréfiés et de grains de café verts pour réguler la pigmentation de la peau WO2012013763A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2013001076A MX350476B (es) 2010-07-30 2011-07-29 Uso de una mezcla de granos de cafe tostados y verdes para regular pigmentacion de la piel.
JP2013521152A JP2013537528A (ja) 2010-07-30 2011-07-29 皮膚色素沈着を調節するための焙煎及び非焙煎コーヒー豆混合物の使用
BR112013002326-0A BR112013002326B1 (pt) 2010-07-30 2011-07-29 uso cosmético de uma mistura de grãos de café torrado
EP11739045.0A EP2598105A2 (fr) 2010-07-30 2011-07-29 Utilisation d'un mélange de grains de café torréfiés et de grains de café verts pour réguler la pigmentation de la peau
RU2013108970/15A RU2013108970A (ru) 2010-07-30 2011-07-29 Применение смеси обжаренных и зеленых кофейных зерен для регулирования пигментации кожи
CN201180037632.XA CN103068360B (zh) 2010-07-30 2011-07-29 烘焙咖啡豆和生咖啡豆的混合物用于调节皮肤色素沉着的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10171378 2010-07-30
EP10171378.2 2010-07-30

Publications (2)

Publication Number Publication Date
WO2012013763A2 true WO2012013763A2 (fr) 2012-02-02
WO2012013763A3 WO2012013763A3 (fr) 2012-03-22

Family

ID=43416913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/063060 WO2012013763A2 (fr) 2010-07-30 2011-07-29 Utilisation d'un mélange de grains de café torréfiés et de grains de café verts pour réguler la pigmentation de la peau

Country Status (7)

Country Link
EP (1) EP2598105A2 (fr)
JP (1) JP2013537528A (fr)
CN (1) CN103068360B (fr)
BR (1) BR112013002326B1 (fr)
MX (1) MX350476B (fr)
RU (1) RU2013108970A (fr)
WO (1) WO2012013763A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102012029163B8 (pt) * 2012-11-13 2022-03-29 Inst Agronomico De Campinas Uso do óleo de café torrado da espécie coffee arábica
JP2015140309A (ja) * 2014-01-28 2015-08-03 一丸ファルコス株式会社 カフェ酸又はカフェ酸誘導体を有効成分とするキネシン抑制剤
CN106074308A (zh) * 2016-08-12 2016-11-09 广西大学 一种富多酚黑糖祛斑面膜的生产工艺
JP2018108977A (ja) * 2016-12-28 2018-07-12 花王株式会社 経口肌荒れ改善剤
CN110946200A (zh) * 2019-12-26 2020-04-03 广州市志泰生物科技有限公司 一种咖啡樱桃保湿美肌饮料及其制备方法
CN113729034A (zh) * 2021-07-30 2021-12-03 阿特美生物科技(海南)有限公司 一种二元喷雾植物萃取物的空气消毒剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871173A1 (fr) 2005-04-12 2008-01-02 Nestec S.A. Produit a base de cafe

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0826967A (ja) * 1994-07-13 1996-01-30 Ichimaru Pharcos Co Ltd クロロゲン酸又はその誘導体含有化粧料
JPH0892057A (ja) * 1994-09-16 1996-04-09 Ichimaru Pharcos Co Ltd コーヒーノキ種子抽出物配合化粧料
JPH09151130A (ja) * 1995-12-01 1997-06-10 Yakurigaku Chuo Kenkyusho:Kk 白毛症および白斑症治療薬
ES2535778T3 (es) * 2002-09-09 2015-05-14 Nestec S.A. Composición de administración oral para mejorar la calidad de la piel
FR2848448B1 (fr) * 2002-12-13 2007-04-06 Oreal Utilisation d'un extrait de grains de cafe decafeine dans la preparation d'une composition destinee a stimuler la fonction sebacee de la peau par administration orale
EP1572145A1 (fr) * 2002-12-13 2005-09-14 L'oreal Utilisation d'un extrait de grains de cafe decafeines dans la preparation d'une composition servant a stimuler la fonction sebacee de la peau administree par voie orale
JP2006335758A (ja) * 2003-10-06 2006-12-14 Oriza Yuka Kk ダイエット用組成物
EP1674106B1 (fr) * 2003-10-06 2011-09-21 Oryza Oil & Fat Chemical Co., Ltd Composition dietetique
MXPA06011530A (es) * 2004-04-08 2007-03-21 Vdf Futureceuticals Inc Composiciones cosmeticas de cereza de cafe y metodos.
US20090169651A1 (en) * 2007-06-28 2009-07-02 Muhammed Majeed Anti-skin damage compositions with complimentary dual mode of action

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871173A1 (fr) 2005-04-12 2008-01-02 Nestec S.A. Produit a base de cafe

Also Published As

Publication number Publication date
MX2013001076A (es) 2013-03-12
WO2012013763A3 (fr) 2012-03-22
CN103068360B (zh) 2015-11-25
BR112013002326A2 (pt) 2016-05-24
RU2013108970A (ru) 2014-09-10
JP2013537528A (ja) 2013-10-03
BR112013002326B1 (pt) 2018-11-27
CN103068360A (zh) 2013-04-24
EP2598105A2 (fr) 2013-06-05
MX350476B (es) 2017-09-07

Similar Documents

Publication Publication Date Title
EP2598103B1 (fr) Utilisation des grains de café pour la regulation de la pigmentation de la peau
WO2012013776A2 (fr) Utilisation de grains de café vert pour réguler des troubles de la pigmentation de la peau
US20060018986A1 (en) Extracts of decaffeinated coffee beans and orally administrable compositions comprised thereof for stimulating the sebaceous function of the skin
WO2012000954A1 (fr) Utilisation d'acide chicorique et de ses dérivés pour réguler la pigmentation de la peau
WO2012013763A2 (fr) Utilisation d'un mélange de grains de café torréfiés et de grains de café verts pour réguler la pigmentation de la peau
ES2923931T3 (es) Producto fermentado y método de producción del mismo
WO2012000957A1 (fr) Utilisation d'acide chicorique et d'une bactérie lactique pour réguler la pigmentation de la peau
WO2012000955A1 (fr) Utilisation de l'acide caftarique et de ses dérivés dans des aliments ou des boissons pour réguler la pigmentation de la peau
EP2598104B1 (fr) Utilisation des grains de café vertes et des produits probiotiques pour la régulation de la pigmentation de la peau
JP2006511603A (ja) 経口投与による皮膚の皮脂腺機能を刺激することを意図した組成物の調製における脱カフェインされたコーヒー豆抽出物の使用
WO2012000959A1 (fr) Utilisation de l'acide caftarique et d'une bactérie lactique dans des aliments ou des boissons pour réguler la pigmentation de la peau
KR102014312B1 (ko) 참까막살 추출물을 유효성분으로 포함하는 피부 미백용 조성물
KR102286969B1 (ko) 정제어유 유래 오메가-7 및 홍삼을 포함하는 피부 상태 개선용 조성물
CN102958500B (zh) 咖啡酰酒石酸及衍生物在食品或饮料中用于调节皮肤色素沉着的用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180037632.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11739045

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013521152

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/001076

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011739045

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013108970

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013002326

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013002326

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130130